![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Amarin Corp | LSE:AMRN | London | Ordinary Share | GB00B29VL935 | ORD 50P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 92.50 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:7652J Amarin Corporation Plc 12 December 2007 AMARIN CORPORATION PLC LONDON, United Kingdom, December 12, 2007, Amarin Corporation plc ("Amarin" or the "Company") announces that it is sending to its shareholders today a Notice of General Meeting and Proxy Form in relation to a General Meeting to be held at 7 Curzon Street, Mayfair, London W1J 5HG at 11 a.m. on 17 January 2008 regarding the consolidation of every ten Ordinary Shares of £0.05 each in the capital of the Company into one Ordinary Share of £0.50 each. A copy of each of the Notice and Proxy Form is available on the Company's website at http://www.amarincorp.com/investor_relations/egm_2008.472.html About Amarin Amarin is committed to improving the lives of patients suffering from central nervous system and cardiovascular diseases. Our goal is to be a leader in the research, development and commercialization of novel drugs that address unmet patient needs. Amarin's CNS development pipeline includes the recently acquired myasthenia gravis phase II clinical program and preclinical programs in neuromuscular, neuronal degenerative and inflammatory diseases; Miraxion for Huntington's disease; two programs in Parkinson's disease; one in epilepsy; and one in memory and cognition. Amarin is initiating a series of cardiovascular preclinical and clinical programs to capitalize on the known therapeutic benefits of essential fatty acids in cardiovascular disease. Amarin also has a proprietary lipid-based technology platform for the targeted transport of molecules through the liver and/or to the brain that can be leveraged in a wide range of disease applications for its own product pipeline or with potential partners. Amarin has its primary stock market listing in the U.S. on the NASDAQ Capital Market ("AMRN") and secondary listings in the U.K. and Ireland on AIM ("AMRN") and IEX ("H2E"), respectively. Contacts: Amarin +44 (0) 207 907 2442 Rick Stewart Chief Executive Officer Alan Cooke President and Chief Financial Officer investor.relations@amarincorp.com Investors: Lippert/Heilshorn & Associates, Inc. Anne Marie Fields +1 212 838 3777 Bruce Voss +1 310 691 7100 Media: Powerscourt +44 (0) 207 250 1446 Rory Godson Sarah Daly Davy: +353 (0)1 679 6363 Ivan Murphy Fergal Meegan Ends. This information is provided by RNS The company news service from the London Stock Exchange END NOEUUOSRBKRUAAA
1 Year Amarin Chart |
1 Month Amarin Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions